when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
calendar
approval

approval

ICLUSIG (PONATINIB HYDROCHLORIDE) — FDA approval

November 28, 2016updated 4mo ago

community read0 votes

Sponsor: TAKEDA PHARMS USA. Form: TABLET. Route: ORAL

view source ↗

Data sources

last refreshed 4mo ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

same company · ±60 days · 4

approvalVYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approvalJan 6, 2017
approvalADDERALL XR 10 (AMPHETAMINE ASPARTATE) — FDA approvalJan 6, 2017
approvalVYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approvalOct 14, 2016
approvalVYVANSE (LISDEXAMFETAMINE DIMESYLATE) — FDA approvalOct 14, 2016

🐶 often sniffed alongside

top 4

company$CAHCARDINAL HEALTH INC1 co-mentions · 1 sources
tagRecall1 co-mentions · 1 sources
drugantihemophilic factor (recombinant)1 co-mentions · 1 sources
drugKovaltry1 co-mentions · 1 sources

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?